Review Article

The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art

Giulia Montori,1 Federico Coccolini,2 Marco Ceresoli,2 Fausto Catena,3 Nicola Colaianni,2 Eugenio Poletti,2 and Luca Ansaloni2

1 General Surgery Department, Spedali Civili, Chirurgia Generale 3, Piazzale Spedali Civili, 25121 Brescia, Italy
2 General Surgery Department, Papa Giovanni XXIII Hospital, 42121 Bergamo, Italy
3 Emergency Surgery Department, Ospedale Maggiore, 43121 Parma, Italy

Correspondence should be addressed to Giulia Montori; giulia.montori@gmail.com

Received 18 July 2013; Revised 20 November 2013; Accepted 2 January 2014; Published 17 February 2014

Academic Editor: George H. Sakorafas

Copyright © 2014 Giulia Montori et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer death in the world [1, 2]. The principal risk factors in development of GC are Helicobacter pylori infection, atrophic gastritis, intestinal metaplasia, dysplasia, male gender, cigarette smoking, partial gastrectomy, Menetrier’s disease, and genetic factors [3].

Global incidence of primary tumour locations and the histological types are constantly changing: in United States and in Western Europe the incidence of esophageal-gastric junction (Barrett’s type) and gastric cardia adenocarcinoma is increasing [4] while there has been a reduction of incidence of distal GC since the 1970s, especially in Western countries [5].

Although GC mortality has been reduced, it remains a disease with poor prognosis and high mortality, second only to lung tumour. The prognosis of GC depends on stage and location: proximal gastric tumours (i.e., cardia tumor) have poorer prognosis compared to those in the pyloric antrum and when the disease is confined to the stomach mucosa, 5-year survival is near to 95%, while the reported 5-year survival rate for advanced GC varies from 10 to 20% [5].

Metastatic dissemination in GC may occur through the hematologic torrent or by dissemination to the peritoneal cavity; this last condition is called peritoneal carcinomatosis (PC) [6], and it is considered a stage IV of GC. Recent studies show that peritoneal dissemination is more frequent than hematogenous metastases. Only 40% of GC deaths have hepatic metastases, while in 53–60% disease evolves through PC [3].

1. Introduction

Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer death in the world [1, 2]. The principal risk factors in development of GC are Helicobacter pylori infection, atrophic gastritis, intestinal metaplasia, dysplasia, male gender, cigarette smoking, partial gastrectomy, Menetrier’s disease, and genetic factors [3].

Global incidence of primary tumour locations and the histological types are constantly changing: in United States and in Western Europe the incidence of esophageal-gastric junction (Barrett’s type) and gastric cardia adenocarcinoma is increasing [4] while there has been a reduction of incidence of distal GC since the 1970s, especially in Western countries [5].

Although GC mortality has been reduced, it remains a disease with poor prognosis and high mortality, second only to lung tumour. The prognosis of GC depends on stage and location: proximal gastric tumours (i.e., cardia tumor) have poorer prognosis compared to those in the pyloric antrum and when the disease is confined to the stomach mucosa, 5-year survival is near to 95%, while the reported 5-year survival rate for advanced GC varies from 10 to 20% [5].

Metastatic dissemination in GC may occur through the hematologic torrent or by dissemination to the peritoneal cavity; this last condition is called peritoneal carcinomatosis (PC) [6], and it is considered a stage IV of GC. Recent studies show that peritoneal dissemination is more frequent than hematogenous metastases. Only 40% of GC deaths have hepatic metastases, while in 53–60% disease evolves through PC [3].
a common manifestation of digestive-tract and gynaecological advanced cancers (such as appendicle tumour, ovarian cancer, colorectal cancer, or gastric cancer). It is generally associated with a poor prognosis; patients with PC of gastric origin have an extremely bad prognosis with a median survival estimate at 1–3 months [3, 14].

Data from the literature show that 15% of patients present PC ab initio and 35% of patients die of intraperitoneal recurrence for PC confined exclusively into the peritoneum [15]. Systemic chemotherapy improves median survival in metastatic gastric cancer to 7–10 months [16], but in patients with PC from GC the same improvement has not been reported [17].

Currently, at the intraoperative abdominal examination, peritoneal seeding is found in 10–20% of patients scheduled for potentially curative resection and in 40% of those at stage II-III [15, 18, 19]; 20–50% of patients treated with radical surgery will develop postoperative peritoneal recurrence [20], and intraperitoneal spread of tumour cells is observed in 54% of patients who died of recurrence after surgery in advanced GC [21].

During the last 30 years multimodal therapeutic approaches on PC improved, resulting in a modified role of surgery: not a simple debulking operation anymore but a complete tumour cytoreduction with no macroscopic residual disease.

Sugarbaker investigated the synergism of the effects of hyperthermia and intraperitoneal anticancer chemotherapy against tumour cells; he found the existence of PC originating by low grade malignancy tumours without invasion capacity (like pseudomyxoma peritonei) that can be treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

In 1995 Sugarbaker definitively codified, in terms of rationale and surgical technique, the procedure of peritomectomy [22]. Following these innovative studies, a growing number of authors have been investigating this procedure [19]. Furthermore, same authors start to test these techniques in more aggressive tumours.

4. Diagnosis of Peritoneal Carcinomatosis

For preoperative diagnosis of PC, useful imaging techniques are ultrasonic (US), computerized tomography (CT), magnetic resonance imaging (MRI), and 18F-Fluorodeoxyglucose Positron Emission Tomography-CT (FDG-PET-CT) [15], but all these imaging techniques have major limitations in diagnosing PC because of the low-volume density of peritoneal nodules. CT and MRI are important mainly in evaluating unresectable disease and cancer staging [26, 27]. PET-CT seem to be a good option, but are expensive and have drawbacks for lesions smaller than 5 mm in diameter [14]. Concerning PC from GC, Yang et al. [28] report an accuracy of PET-CT of 87%, with a sensitivity and specificity of 72.7% and 93.6%, respectively, with a sensitivity better than CT, while for primary GC and lymph node metastases the accuracy for PET-CT is 54%. CT is not accurate (8–17% of sensitivity) particularly for malignant granulations less than 5 mm in diameter and for small bowel nodulations.

Due to the low accuracy given by the imaging, the main diagnosing methods currently used to evaluate peritoneal surface are diagnostic laparoscopy or laparotomy and peritoneal cytological examination that have been published until today as follows.

(i) Japanese rules of GC [14, 29] is a classification into five categories that only considers the presence of cancerous implants and/or of malignant cells in the peritoneal washing fluid, without considering the size of malignant nodules.

(ii) Gilly staging system for PC [14, 19], also called the Lyon score, is based on the size and distribution of malignant nodules (localized or diffused). It demonstrates that the use of complete (R0-RI) or incomplete (R2) cytoreduction, in order to assess the entirety of surgical clearance of cancer, is successful. It is difficult to confirm a R0 resection in patients with carcinomatosis. R0 and R1 can be grouped together as the outcome of these two groups is very similar. This system was also revealed to be an important prognostic indicator, as the median survival of patients with stage I or II is significantly higher than those with stage III or IV, and they can be candidates for CRS and HIPEC. However, this system does not clearly indicate the potential resectability of PC [5].
Common contraindications for HIPEC are age >70 yrs, important comorbidities, clinical aggravation with systemic chemotherapy, malnutrition, extra abdominal metastases, liver metastases when unresectable, and massive retropertitoneal bulk disease or lymph node involvement. Other minor exclusion criteria are Body Mass Index (BMI) >40, history of pelvic irradiation, carcinomatosis extended at the CT or clinically significant, more than 4 surgical procedures, occlusion, and no drop markers with neoadjuvant chemotherapy [19].

Different studies presented contrasting data about survival rates; however, they all agreed with the necessity of a complete (Tables I and 2) cytoreduction to improve survival. HIPEC has an adjuvant role to prevent peritoneal recurrences [19]. Gill et al. show that in patients with a CC (completeness of cytoreduction) score of 0 or 1 overall median survival was 15 months [10] (versus 7.9 months in patients with CC 2 score), with an overall mortality rate of 4.8%.

Yonemura et al. [8] in an RCT of 139 patients with T2-4 GC randomized into 3 groups (HIPEC and surgery, intra-peritoneal normothermic chemotherapy plus surgery, and surgery alone) show that in the first group the survival rate was significantly higher (61% versus 43% and 42% of the other two groups), particularly in patients with peritoneal infiltration and lymph node positive metastases. Similar results were published by Fujimoto et al. [21] in stage II-III GC patients, and by Kim and Bae [7] in patients affected by stage III and IV GC treated with HIPEC + CRS versus surgery alone.

Kim and Bae [7] analysed 103 patients with GC stage III-IV: 51 underwent surgical resection alone and 52 received surgery plus HIPEC. Mitomycin-C at 44°C was used in the HIPEC group as intraperitoneal chemotherapy. The 5 years overall survival rate in the 103 patients was 29.97%. It was higher but not statistically significant in the HIPEC + CRS group (32.7% versus 27.1% control group). The difference, considering exclusively the survival rate of the 65 patients with stage III GC, was statistically significant (58.6% versus 44.4% control group).

In a retrospective multicentric French study undertaken between February 1989 and August 2007, Glehen et al. [10] evaluated 159 patients that underwent cytoreductive surgery and perioperative intraperitoneal chemotherapy (HIPEC and EPIC or both) and showed 1-, 3-, and 5-year survival rates of 43%, 18%, and 13%, respectively, that increase up to 61%, 30%, and 23%, respectively, in patients with a complete cytoreduction. Thanks to multivariate analysis, the authors reported the completeness of cytoreduction as being the principal independent prognostic factor. In order to correctly execute cytoreduction, the staging system should be corroborated by PCI assessment. The study showed that if cytoreductive surgery does not allow a sufficient downstaging, particularly in HIPEC, the survival rates are poor (median survival of 6–8 months).

Three recent meta-analysis [11–13] of RCTs, assessing patients with GC (with or without PC), demonstrates the survival benefit offered by HIPEC. Already in 2007, Yan et al. [11] conducted 13 studies on 1648 patients and demonstrated the positive effects in terms of overall survival rates, when adding HIPEC or HIPEC with EPIC to surgery. These studies also showed how these procedures can be complementary to

5. Rationale and Technique of Cytoreduction and HIPEC

Pharmacokinetic and peritoneal permeability studies demonstrate a higher intraperitoneal concentration of drugs with chemotherapy administered intraperitoneally than with systemic administration [23, 24]. The peritoneal plasma barrier maintains a positive gradient of chemotherapy in the peritoneum, increasing the local effects of the drugs and reducing the systemic toxicity [3]. Moreover, when chemotherapy treatment is associated with hyperthermia, the locoregional effects are considerably extended, with an increased penetration up to 3–6 mm into malignant nodules and an increased antimitotic effect. Several studies confirm that hyperthermia (42–43°C) enhances the effects of antitumoral drugs, especially of oxaliplatin, mitomycin C, doxorubicin, cisplatin, paclitaxel, and irinotecan [19], also increasing the chemosensitivity of neoplastic cells. The intraabdominal temperature, however, should not exceed the temperature of 43°C, in order to avoid the risk of bowel perforation [12].

According to surgical-oncologic principles, the treatment of non-metastatic GC consists of resection with total gastrectomy and D1 and/or D2 lymphadenectomy [3]. Different trials proposed multiple chemotherapy protocols using drugs like Epirubicine, Cisplatin and 5-Fluorouracil (ECF), or Epirubicin, Cisplatin and Capecitabina (ECX), that do not need a central venous access device [3].

S-1, a new drug recently introduced in Japan, combined with Cisplatinum, Paclitaxel, Docetaxel or Irinotecan has become the standard treatment for PC from GC [14].

6. Cytoreductive Surgery and HIPEC for Advanced Gastric Cancer

Correct radiological, clinical, and cytological stadiation is essential requirement for a better prognosis after HIPEC in GC. It is necessary to distinguish PC in early or advanced GC from PC as a recurrence of already operated GC. In fact, in the former case it is easier to succeed with a complete cytoreduction (CCR-0, R0), while in the latter, previous surgical treatment and adhesion development decrease the possibility to achieve a complete cytoreduction.
Table 1: Comparing main studies in terms of median survival, 5-year survival rates, and morbidity.

| Authors                  | Year published | Type of study | Stage of GC | Number of patients | Type of protocol                        | Median survival (months) | 5-year survival rates | Morbidity |
|--------------------------|----------------|---------------|-------------|--------------------|----------------------------------------|--------------------------|-----------------------|-----------|
| Fujimoto et al. [21]     | 1999           | RCT           | Stage II-III| 141                | HIPEC + surgery versus surgery alone   | N/A                      | 76% versus 57%        | N/A       |
| Kim and Bae [7]          | 2001           | PCS           | Stage III-IV| 103                | HIPEC + CRS versus surgery alone       | 36 versus 22.9           | 32.7% versus 27.1%    | 33.2%     |
| Yonemura et al. [8]      | 2001           | RCT           | Stage II-III| 139                | HIPEC + surgery versus NIC + surgery versus surgery alone | N/A                      | 61% versus 43%        | 4% versus 0%  |
| Yonemura et al. [9]      | 2009           | PCS           | Stage III-IV| 79                 | NIPS versus NIPS + surgery              | N/A                      | 20.4% versus 40%*     | 11.4%     |
| Glehen et al. [10]       | 2010           | RCS           | Stage III-IV| 159                | HIPEC + EPIC versus EPIC HIPEC          | 9.2 (overall)            | 13% (overall)         | 27.8%     |

HIPEC: hyperthermic intraperitoneal chemotherapy; EPIC: early postoperative intraperitoneal chemotherapy; PIC: perioperative intraperitoneal chemotherapy; NIPS: neoadjuvant intraperitoneal and systemic chemotherapy; NIIC: normothermic Intraoperative Intraperitoneal Chemotherapy; DPIC: Delayed Postoperative Intraperitoneal Chemotherapy; RCS: Retrospective Case Series; PCS: Prospective cohort study; N/A: not available.

* 2-year survival rates.

Table 2: Comparing main meta-analysis in terms of overall survival and morbidity.

| Authors                  | Year published | Type of study | Stage of GC | Number of patients | Type of protocol                        | Overall survival | Peritoneal recurrence | Mortality and morbidity |
|--------------------------|----------------|---------------|-------------|--------------------|----------------------------------------|------------------|-----------------------|-------------------------|
| Yan et al. [11]          | 2007           | Meta-analysis (13 RCTs) | Stage I–IV  | 1648               | Surgery + HIPEC/HEPIC + EPIC/NIIC versus surgery alone ± systemic chemotherapy | HR = 0.60¹      | RR = 0.84⁵            | RR = 1.43               |
|                          |                |               |             |                    |                                         | HR = 0.45²       | RR = 0.51             | RR = 1.01/1.81/0.76/2.37/4.33⁷ |
|                          |                |               |             |                    |                                         | HR = 0.67³       | RR = 1.00⁶            |                         |
| Jin-Yu et al. [12]       | 2012           | Meta-analysis (15 RCTs) | N/A         | 1713               | HIPEC versus HIPEC + PIC versus NIIC   | HR = 0.60        | OR = 2.29              |                         |
|                          |                |               |             |                    |                                         | HR = 0.47        | OR =                  |                         |
|                          |                |               |             |                    |                                         | HR = 0.70        | 1.04/2.60/1.61/0.39/5.74/3.67/3.57⁴ |
| Sun et al. [13]          | 2012           | Meta-analysis (10 RCTs) | Stage II-III | 1062              | HIPEC* versus surgery                    | MMC RR = 0.75    | RR = 0.45              | N/A for Mortality       |
|                          |                |               |             |                    |                                         | 5-FU RR = 0.69   | RR =                   |                         |
|                          |                |               |             |                    |                                         |                  | RR = 1.68/0.52/1.38/0.79/1.47⁶ |

HR: hazard ratio; RR: risk ratio; OR: odds ratio; MMC: mitomycin C; 5-FU: 5-fluorouracil; HIPEC: hyperthermic intraperitoneal chemotherapy; EPIC: early postoperative intraperitoneal chemotherapy; PIC: perioperative intraperitoneal chemotherapy; NIIC: normothermic intraoperative intraperitoneal chemotherapy; RCS: retrospective case series; PCS: prospective case series; N/A: not available; PC: peritoneal carcinomatosis.

¹²³HIPEC, HIPEC + EPIC, and NIIC, respectively.
⁴No differences in morbidity between HIPEC and NIIC groups and the respective control arms.
⁵Morbidity of anastomotic leak, bowel fistula, pancreatic fistula, intra-abdominal abscess, and neutropenia, respectively.
* Data calculated with risk ratio (RR) and divided in two subgroups for analysis: mitomycin C subgroup RR = 0.75, 5-Fluorouracil RR = 0.69 versus control group RR = 0.45.
⁶Morbidity of bone marrow suppression, anastomotic leak, bowel fistula, adhesive ileus, and liver dysfunction, respectively.
⁷Morbidity of anastomotic leak, ileus, bowel perforation, pancreatic fistula, marrow depression, fever, and intra-abdominal abscess, respectively.

Adjuvant systemic treatment. The efficacy of normothermic intraperitoneal chemotherapy (NIIC) is marginal. Jin-Yu et al. [12] analyzed 15 RCTs and demonstrated that HIPEC and NIIC should be recommended in treating patients with GC, as they significantly improve the overall survival rates. HIPEC results are better, but NIIC’s are still statistically significant [8]. This meta-analysis demonstrated that adding postoperative intraperitoneal chemotherapy (PIC) to HIPEC has no additional effect on overall survival rates but it improves costs and toxicity. This study also showed that intraperitoneal chemotherapy (IPC) has no effect on prevention of lymph metastasis, but could decrease by 73% the rate of hepatic metastasis. Authors demonstrated that IPC does not increase perioperative mortality and postoperative anastomotic leaks, ileus, or bowel perforation rates, but it increases the risk of marrow depression, intra-abdominal abscess, and fever. The same results are also confirmed by Sun et al. [13].
In the last decade an interesting new drug, called Catumaxomab, has been developed in Germany [31]. The Catumaxomab is a rat-mouse hybrid monoclonal antibody that is now used for patients with malignant ascites in phase II/III randomized trial. Two studies [32, 33] demonstrate that this drug seems to improve progression-free survival in patients with GC (median 71 versus 44 days; \( P = 0.03 \)) and that it seems to improve the survival in gastrointestinal EpCAM+ tumours (EpCAM: antiepithelial cell adhesion molecule) in intraperitoneal use. However, final results of both studies have yet to be published.

CRS and HIPEC are associated with significant morbidity and mortality, also in high volume centers, and reported rates are included between 0.9–5.8% and 12–52%, respectively [34]. The main postoperative complications after CRS and HIPEC are intra-abdominal abscess, gastric or small intestinal perforation, postoperative ileus, anastomotic leakage, postoperative bleeding, fistula, sepsis, respiratory distress, hematologic toxicity, and urinary disturbance [6, 19]. In the same group of patients, the main causes of death include anastomotic leakage, sepsis, postoperative bleeding, intestinal fistula, and disseminated intravascular coagulation (DIC) [35].

The aggressiveness of GC disease is the main cause of this unfavourable prognosis. Recently, Yonemura et al. [9, 14] proposed a multimodal strategy that associates neoadjuvant intraperitoneal and systemic chemotherapy (NIPS), CRS + HIPEC and EPIC. The rationale of this method is to reduce tumour burden before surgery with NIPS, a bidirectional HIPEC and EPIC. The aim of EPIC is then to eradicate residual intraperitoneal cancer cells before the development of adhesions.

The NIPS technique is characterized by a first phase in which patients are treated with 60 mg/m² of oral S-1 for 21 days, followed by one week of rest. A port system has been previously placed into the abdominal cavity under local anesthesia, with the tip in the Douglas pouch. On the 1st, 8th, and 15th postoperative days, 30 mg/m² of Taxotere and 30 mg/m² of Cisplatinum with 500 mL of saline are infused into the peritoneal cavity. Authors recommend two cycles of treatment to achieve a negative cytology status. Complications after NIPS have been reported in 4 out of 79 patients (1 with grade 4 of bone marrow toxicity, 3 with a renal dysfunction). In 3 patients, infections around the periporal space, that led to the port remotion, were reported. This study shows a washing cytology negativization in 41 out of 79 patients (63%) [4].

Also Glehen et al. [10], in a retrospective multicentre study, recommend the routine use of neoadjuvant chemotherapy to improve surgical results and to exclude patients who do not respond to the therapy form HIPEC treatment.

7. Conclusions

The aforementioned procedures should be exclusively performed in highly experienced centres because of the special surgical expertise needed to achieve high rates of complete cytoreduction [14, 19, 23, 32-34].

Patient selection is very crucial and should be carried out by a multidisciplinary group of specialists (anaesthesists, surgeons, clinicians, and oncologists) in order to achieve better results and to reduce the high costs related to these procedures and relevant complications.

An interdisciplinary approach should be developed further: the association of NIPS, CRS, HIPEC, and EPIC could increase the rate of CC-0 procedures and consequently survival rates, particularly for PCI ≤ 6 [5, 11, 21, 32]. Neoadjuvant chemotherapy, routinely recommended for management of GC without PC, may improve survival also in PC from GC [10, 34–37] and adjuvant chemotherapy could prevent recurrence from GC [10]. Finally, the study of molecular and serum tumour markers could provide valuable prognostic information and would allow for a better selection of subsequent treatment combinations [14, 38].

Conflict of Interests

All authors declare that there is no conflict of interests.

Acknowledgment

Thanks are due to Ramona Ruggeri for proofreading.

References

[1] P. Bertuccio, L. Chatenoud, F. Levi et al., “Recent patterns in gastric cancer: a global overview,” International Journal of Cancer, vol. 125, no. 3, pp. 666–673, 2009.
[2] D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” CA Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005.
[3] A. Okines, M. Verheij, W. Allum, D. Cunningham, and A. Cervantes, “Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 21, no. 5, pp. v50–v54, 2010.
[4] A. Nissan, A. Garofalo, and J. Esquivel, “Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for gastric adenocarcinoma: why haven’t we reached the promised land?” Journal of Surgical Oncology, vol. 102, no. 5, pp. 359–360, 2010.
[5] O. Glehen, F. Mohamed, and F. N. Gilly, “Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia,” The Lancet Oncology, vol. 5, no. 4, pp. 219–228, 2004.
[6] R. S. Gill, D. P. Al-Adra, J. Nagendran et al., “Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity,” Journal of Surgical Oncology, vol. 104, no. 6, pp. 692–698, 2011.
[7] J.-Y. Kim and H.-S. Bae, “A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP),” Gastric Cancer, vol. 4, no. 1, pp. 27–33, 2001.
[8] Y. Yonemura, X. de Aretxabala, T. Fujimura et al., “Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to
gastric cancer: final results of a randomized controlled study,”*Hepato-Gastroenterology*, vol. 48, no. 42, pp. 1776–1782, 2001.

[9] Y. Yonemura, Y. Endou, M. Shino et al., “Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery,”*Journal of Surgical Oncology*, vol. 100, no. 4, pp. 311–316, 2009.

[10] O. Glehen, F. N. Gilly, C. Arvieux et al., “Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy,” *Annals of Surgical Oncology*, vol. 17, no. 9, pp. 2370–2377, 2010.

[11] T. D. Yan, D. Black, P. H. Sugarbaker et al., “A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer,” *Annals of Surgical Oncology*, vol. 14, no. 10, pp. 2702–2713, 2007.

[12] H. Jin-Yu, Y.-Y. Xu, Z. Sun et al., “Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis,” *Asian Pacific Journal of Cancer Prevention*, vol. 13, no. 9, pp. 4379–4385, 2012.

[13] J. Sun, Y. Song, Z. Wang et al., “Benefit of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials,” *BMC Cancer*, vol. 12, article 526, 2012.

[14] Y. Yonemura, A. Elnemr, Y. Endou et al., “Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer,” *World Journal of Gastrointestinal Oncology*, vol. 2, no. 2, pp. 85–97, 2010.

[15] F. Carboni, A. di Giorgio, L. di Lauro et al., “Criteri di appropriatezza clinica ed organizzativa nella diagnosi, terapia e follow-up delle carcinosi peritoneali,” SICO, 2012, http://www.siconline.org/00_allegati_news/15_CarcinosiPeritoneali.pdf.

[16] S. Pyrhonen, T. Kuitunen, P. Nyandoto, and M. Kouri, “Randomised comparison of fluorouracil, epideroxorubicin and methotrextate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer,” *British Journal of Cancer*, vol. 71, no. 3, pp. 587–591, 1995.

[17] K. Hanazaki, Y. Mochizuki, T. Machida et al., “Post-operative chemotherapy in non-curable gastrectomy for advanced gastric cancer,” *Hepato-Gastroenterology*, vol. 46, no. 26, pp. 1238–1243, 1999.

[18] Y. Kodera, Y. Yamamura, Y. Shimizu et al., “Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection,” *Journal of Surgical Oncology*, vol. 72, no. 2, pp. 60–64, 1999.

[19] F. Roviello, S. Caruso, D. Marrelli et al., “Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments,” *Surgical Oncology*, vol. 20, no. 1, pp. e38–e54, 2011.

[20] F. Roviello, D. Marrelli, A. Neri et al., “Treatment of peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP): postoperative outcome and risk factors for morbidity,” *World Journal of Surgery*, vol. 30, no. 11, pp. 2033–2040, 2006.

[21] S. Fujimoto, M. Takahashi, T. Mutou et al., “Successful intraperitoneal hyperthermic chemoperfusion for the prevention of post-operative peritoneal recurrence in patients with advanced gastric carcinoma,” *Cancer*, vol. 85, no. 3, pp. 529–534, 1999.

[22] P. H. Sugarbaker, “Peritonyectomy procedures,” *Annals of Surgery*, vol. 221, no. 1, pp. 29–42, 1995.

[23] P. H. Sugarbaker, “Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis,” *Seminars in Surgical Oncology*, vol. 14, no. 3, pp. 254–261, 1998.

[24] P. H. Sugarbaker, “Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology,” in *Peritoneal Carcinomatosis: Principles and Management*, pp. 79–100, Kluwer Academic, Boston, Mass, USA, 1996.

[25] Y. Yonemura, N. Nojima, T. Kawamura et al., “Mechanisms of formation of peritoneal dissemination,” in *Peritoneal Dissemination: Molecular Mechanisms and the Latest Therapy*, pp. 1–46, Maeda Shoten, Kanazawa, Japan, 1998.

[26] J. H. Stewart IV, P. Shen, A. Edward et al., “Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions,” *Annals of Surgical Oncology*, vol. 12, no. 10, pp. 765–777, 2005.

[27] R. S. Gill, D. Al-Adra, J. Nagendran et al., “Treatement of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity,” *Journal of Surgical Oncology*, vol. 104, no. 6, pp. 692–698, 2011.

[28] Q.-M. Yang, T. Kawamura, H. Itoh et al., “Is PET-CT suitable for predicting lymph node status for gastric cancer?” *Hepato-Gastroenterology*, vol. 55, no. 82–83, pp. 782–785, 2008.

[29] Japanese Research Society for Gastric Cancer, *The General Rules for Gastric Cancer Study*, Kanahara Shuppan, Tokyo, Japan, 1st edition, 1995.

[30] P. Jacquet and P. H. Sugarbaker, “Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis,” in *Peritoneal Carcinomatosis: Principles of Management*, P. H. Sugarbaker, Ed., pp. 359–374, Kluwer Academic, Boston, Mass, USA, 1996.

[31] L. Ansaloni, M. Lotti, and L. Campanati, “The prevention and treatment of peritoneal carcinomatosis from gastric cancer: a 2013 update,” *Journal of Cancer Research & Therapy*, vol. 1, no. 1, pp. 54–59, 2013.

[32] M. M. Heiss, P. Murawa, P. Koralewski et al., “The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial,” *International Journal of Cancer*, vol. 127, no. 9, pp. 2209–2221, 2010.

[33] M. A. Ströhlein, F. Lordick, D. Rüttinger et al., “Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial,” *Onkologie*, vol. 34, no. 3, pp. 101–108, 2011.

[34] I. T. Konstantinidis, C. Young, V. L. Tsikitis et al., “Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: the University of Arizona early experience,” *World Journal of Gastrointestinal Surgery*, vol. 4, no. 6, pp. 135–140, 2012.

[35] A. Mizumoto, E. Canabay, M. Hiranouand et al., “Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan,” *Gastroenterology Research and Practice*, vol. 2012, Article ID 836425, 5 pages, 2012.

[36] S. Fujimoto, M. Takahashi, T. Mutou et al., “Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery,” *Cancer*, vol. 79, no. 5, pp. 884–891, 1997.
[37] O. Glehen, V. Schreiber, E. Cotte et al., “Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer,” *Archives of Surgery*, vol. 139, no. 1, pp. 20–26, 2004.

[38] W. Allum, A. Garofalo, M. Degiuli, and C. Schuhmacher, “The first European union network of excellence for gastric cancer conference, Rome, Italy, April 2008,” *Gastric Cancer*, vol. 12, no. 1, pp. 56–65, 2009.